Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

Continued Strong Growth with WAKIX® Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,800...

Related Keywords

United Kingdom ,United States ,Americans ,Jeffreym Dayno ,Luis Sanay ,Company Updates ,Harmony Biosciences Holdings Inc ,Drug Administration ,Paragon Biosciences ,Zynerba Pharmaceuticals ,Company Nasdaq ,European Union ,Acquisition Of Zynerba Pharmaceuticals ,Exchange Commission ,Million Share Repurchase Program ,Continued Strong Growth ,Net Revenue ,Third Quarter ,Pursue Idiopathic Hypersomnia Indication ,Next Step ,Full Data Set ,Diversified Pipeline ,Pivotal Phase ,Common Stock ,Directors Authorized New ,Share Repurchase ,Held Today ,Biosciences Holdings ,Chief Executive Officer ,Commercialization Agreement ,Operating Expenses ,Myotonic Dystrophy ,Call Today ,Prescribing Information ,Harmony Biosciences ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Annual Report ,Biosciences Investor Contact ,Biosciences Media Contact ,Markets ,